Back to top

Gilead Sciences, Inc. (GILD)

(Delayed Data from NSDQ)

$68.02 USD


+0.42 (0.62%)

Updated May 18, 2018 04:00 PM ET

Add to portfolio

3-Hold     3    

B Value | F Growth | F Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.


Zacks Equity Research

Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.


Zacks Equity Research

5 Value Stocks to Book Gains Using Price-to-Book Ratio

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.


Mark Vickery

Top Stock Reports for BP, Gilead, Enterprise Products & Colgate

Today's Research Daily features new research reports on 17 major stocks, including BP (BP), Gilead (GILD), Enterprise Products (EPD) and Colgate (CL).


Zacks Equity Research

Company News for May 3, 2018

Companies in The News are: SNAP,GILD,MA,UNM


Zacks Equity Research

Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.


Zacks Equity Research

Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV

Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.


Mark Vickery

Apple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUS

Earnings topped the Zacks consensus by 4 cents to $2.73 per share on $61.1 billion in sales.


Madeleine Johnson

Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%

Gilead Sciences Inc. (GILD) just released its latest quarterly financial results, posting earnings of $1.48 and revenues of $5.1 billion.


Zacks Equity Research

Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?

Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.


Zacks Equity Research

What's in Store for ImmunoGen (IMGN) This Earnings Season?

ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.


Zacks Equity Research

Will Agenus (AGEN) Disappoint Investors This Earnings Season?

Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.


Zacks Equity Research

Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.


Zacks Equity Research

HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.


Zacks Equity Research

What's in the Cards for Conatus (CNAT) This Earnings Season?

Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.


Zacks Equity Research

Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.


Zacks Equity Research

Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?

Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.


Zacks Equity Research

What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .


Zacks Equity Research

What's in the Offing for Keryx (KERX) This Earnings Season?

Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.


Zacks Equity Research

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.


Zacks Equity Research

Is a Beat in Store for Alexion (ALXN) This Earnings Season?

Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.


Sweta Killa

Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.


Zacks Equity Research

Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.


Mark Vickery

Top Research Reports for IBM, McDonald's & Gilead

Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), McDonald's (MCD) and Gilead (GILD).


Zacks Equity Research

Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.


Zacks Equity Research

Gilead (GILD) Presents Encouraging Data on NASH Therapies

Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.


Zacks Equity Research

Bristol-Myers Collaborates With Harvard Fibrosis Network

Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.


Zacks Equity Research

Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.


Kinjel Shah

Novartis and Other Drug Stocks With FDA Catalysts in April

With just a quarter gone by this year, the FDA has already granted approval to six new treatments.


Zacks Equity Research

Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.